Video

Dr. Armstrong on recent ARCHES data in metastatic hormone-sensitive prostate cancer

“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.

In this video, Andrew J. Armstrong, MD, MSc, discusses new data from the ARCHES trial, including “Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES,” which was presented at the 2022 American Society of Clinical Oncology Annual Meeting. Armstrong is a professor of medicine, professor in surgery, professor in pharmacology and cancer biology, and a member of the Duke Cancer Institute at Duke University in Durham, North Carolina.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
1 KOL is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.